Ariad, Cephalon Make ASH Splash: BioBuzz By Adam Feuerstein 12/08/09 - 10:45 AM EST
CAMBRIDGE, Mass. (TheStreet) -- An early-stage leukemia drug from Ariad Pharmaceuticals(ARIA Quote) generated some positive buzz at the American Society of Hematology (ASH) annual meeting. Data from a Phase I study of AP24534 showed that the drug had activity in patients with resistant or refractory chronic myeloid leukemia (CLL) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ CLL.) These are hard-to-treat patients because current leukemia drugs, including Novartis'(NVS Quote) Gleevec and Tasigna and Bristol-Myers Squibb's(BMY Quote) Sprycel, have limited or no positive effect. Ariad wants to start a pivotal study in refractory CML patients next year, but the bigger news may come if the company can find a Big Pharma partner for the drug. Ariad shares were up 4% to $2.57 in recent trading. In other ASH-related news, the body of clinical data supporting use of Cephalon's(CEPH Quote) Treanda as a new standard of care in first-line non-Hodgkin's lymphoma (NHL) continues to grow. http://www.thestreet.com/_aol/story/10640902/1/ariad-cephalon-make-ash-splash-biobuzz.html?cm_ven=AOL&cm_cat=Free&cm_pla=Feed&cm_ite=Feed
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.